CHMP backs GSK’s asthma antibody and Novartis’ heart failure drug – PMLiVE


PMLiVE

CHMP backs GSK's asthma antibody and Novartis' heart failure drug
PMLiVE
GlaxoSmithKline's mepolizumab for severe asthma and Novartis new' heart failure therapy Entresto have been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The panel issued positive opinions for the two drugs …

and more »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.